NCT06711055

Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer

A Cohort Study of Adjuvant Therapy With Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 285 (estimated)
• Sponsor: Shu Wang · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and high risk of recurrence and metastasis. HER2 targeted drugs has greatly improved the prognosis and survival of such patients. At present, for HER2 positive breast cancer patients with negative lymph nodes, chemotherapy drugs combined with trastuzumab is the current standard treatment scheme, and in most cases, chemotherapy uses a combination of two drugs, while the main beneficiaries of the trastuzumab and paltuzumab are concentrated in the group of patients with positive lymph nodes. Can targeted therapy be used to reduce the progression of chemotherapy and further achieve efficient and low toxicity strategies. To explore the efficacy and safety of adjuvant therapy of taxane chemotherapy combined with trastuzumab targeting therapy for low-risk HER2 positive and lymph node negative early breast cancer.

Conditions

• HER2-positive Breast Cancer

Timeline

• Start date: 2015-01-01
• Primary completion: 2031-12-31
• Completion: 2031-12-31
• First posted: 2024-12-02
• Last updated: 2024-12-02

Locations

1 site across 1 country: China